Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune responses and permits long-term islet allograft acceptance

Transplantation

Volumn 96, Issue 5, 2013, Pages 454-462

  Watanabe, Masaaki ^a   Yamashita, Kenichiro ^a   Kamachi, Hirofumi ^a   Kuraya, Daisuke ^a   Koshizuka, Yasuyuki ^a   Shibasaki, Susumu ^a   Asahi, Yoh ^a   Ono, Hitoshi ^a   Emoto, Shin ^a   Ogura, Masaomi ^a   Yoshida, Tadashi ^a   Ozaki, Michitaka ^a   Umezawa, Kazuo ^b   Matsushita, Michiaki ^a   Todo, Satoru ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

DHMEQ; Nuclear factor JB; Pancreatic islet transplantation

Indexed keywords

DEHYDROXYMETHYLEPOXYQUINOMICIN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TACROLIMUS;

ALLOIMMUNITY; ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL;

ANIMALS; BENZAMIDES; CYCLOHEXANONES; CYTOKINES; DENDRITIC CELLS; GRAFT SURVIVAL; HMGB1 PROTEIN; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; NF-KAPPA B; POSTOPERATIVE COMPLICATIONS; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84883559665     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31829b077f     Document Type: Article

References (43)

1. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230
2. Hering BJ, Kandaswamy R, Harmon JV, et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 2004; 4: 390
3. Froud T, Baidal DA, Faradji R, et al. Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. Transplantation 2008; 86: 1695
4. Posselt AM, Szot GL, Frassetto LA, et al. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation 2010; 90: 1595
5. Matsumoto S, Takita M, Chaussabel D, et al. Improving efficacy of clinical islet transplantation with iodixanol-based islet purification, thymoglobulin induction, and blockage of IL-1beta and TNF-alpha. Cell Transplant 2011; 20: 1641
6. Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of clinical islet transplantation: 1999Y2010. Diabetes Care 2012; 35: 1436
7. Satoh M, Yasunami Y, Matsuoka N, et al. Successful islet transplantation to two recipients from a single donor by targeting proinflammatory cytokines in mice. Transplantation 2007; 83: 1085
8. Piemonti L, Leone BE, Nano R, et al. Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes 2002; 51: 55
9. Matsuoka N, Itoh T, Watarai H, et al. High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. J Clin Invest 2010; 120: 735
10. Johansson H, Lukinius A, Moberg L, et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 2005; 54: 1755
11. Lai Y, Chen C, Linn T. Innate immunity and heat shock response in islet transplantation. Clin Exp Immunol 2009; 157: 1
12. Alam MU, Harken JA, Knorn AM, et al. Transgenic expression of Hsc70 in pancreatic islets enhances autoimmune diabetes in response to beta cell damage. J Immunol 2009; 183: 5728
13. Joffre O, Nolte MA, Sporri R, et al. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev 2009; 227: 234
14. Andrade CF, Waddell TK, Keshavjee S, et al. Innate immunity and organ transplantation: the potential role of toll-like receptors. Am J Transplant 2005; 5: 969
15. LaRosa DF, Rahman AH, Turka LA. The innate immune system in allograft rejection and tolerance. J Immunol 2007; 178: 7503
16. Hayden MS,West AP, Ghosh S. NF-kappaB and the immune response. Oncogene 2006; 25: 6758
17. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749
18. Kaisho T, Tanaka T. Turning NF-kappaB and IRFs on and off in DC. Trends Immunol 2008; 29: 329
19. Ariga A, Namekawa J, Matsumoto N, et al. Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem 2002; 277: 24625
20. Yamamoto M, Horie R, Takeiri M, et al. Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues. J Med Chem 2008; 51: 5780
21. Funakoshi T, Yamashita K, Ichikawa N, et al. A novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice. J Crohns Colitis 2012; 6: 215
22. Suzuki T, Yamashita K, Jomen W, et al. The novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin, prevents local and remote organ injury following intestinal ischemia/reperfusion in rats. J Surg Res 2008; 149: 69
23. Ueki S, Yamashita K, Aoyagi T, et al. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin. Transplantation 2006; 82: 1720
24. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331
25. Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 2007; 220: 35
26. Saisho Y, Hirose H, Horimai C, et al. Effects of DHMEQ, a novel nuclear factor-kappaB inhibitor, on beta cell dysfunction in INS-1 cells. Endocr J 2008; 55: 433
27. Kuraya D, Watanabe M, Koshizuka Y, et al. Efficacy of DHMEQ, a NF-kB inhibitor, in Islet transplantation: I. HMGB1 suppression by DHMEQ prevents early islet graft damage. Transplantation 2013; 96: 445
28. Dumitriu IE, Baruah P, Valentinis B, et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 2005; 174: 7506
29. Han J, Zhong J, Wei W, et al. Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice. Diabetes 2008; 57: 2118
30. Palumbo R, Galvez BG, Pusterla T, et al. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NFkappaB activation. J Cell Biol 2007; 179: 33
31. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191
32. Chen C, Moreno R, Samikannu B, et al. Improved intraportal islet transplantation outcome by systemic IKK-beta inhibition: NF-kappaB activity in pancreatic islets depends on oxygen availability. Am J Transplant 2011; 11: 215
33. Gao Q, Ma LL, Gao X, et al. TLR4 mediates early graft failure after intraportal islet transplantation. Am J Transplant 2010; 10: 1588
34. Takahashi T, Matsumoto S, Matsushita M, et al. Donor pretreatment with DHMEQ improves islet transplantation. J Surg Res 2010; 163: e23
35. Rossi M, Young JW. Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J Immunol 2005; 175: 1373
36. Jarrossay D, Napolitani G, Colonna M, et al. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 2001; 31: 3388
37. Fonteneau JF, Gilliet M, Larsson M, et al. Activation of influenza virusspecific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity. Blood 2003; 101: 3520
38. Shinoda K, Nakagawa K, Kosaka T, et al. Regulation of human dendritic cells by a novel specific nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin. Hum Immunol 2010; 71: 763
39. Hutton MJ, Westwell-Roper C, Soukhatcheva G, et al. Islet allograft rejection is independent of toll-like receptor signaling in mice. Transplantation 2009; 88: 1075
40. Suzuki Y, Sugiyama C, Ohno O, et al. Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel NF-JB inhibitor. Tetrahedron 2004; 60: 7061
41. Shibasaki S, Yamashita K, Yanagawa Y, et al. Dendritic cells conditioned with NK026680 prolong cardiac allograft survival in mice. Transplantation 2012; 93: 1229
42. Goto R, Yamashita K, Aoyagi T, et al. Immunomodulatory effect of nuclear factor-kappaB inhibition by dehydroxymethylepoxyquinomicin in combination with donor-specific blood transfusion. Transplantation 2012; 93: 777
43. Yamada S, Yakabe K, Ishii J, et al. New high mobility group box 1 assay system. Clin Chim Acta 2006; 372: 173.